Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
详细信息 查看全文
- 作者：Shom Goel1 ; shom_goel@dfci.harvard.edu" class="auth_mail" title="E-mail the corresponding author ; Qi Wang2 ; 16 ; April C. Watt2 ; Sara M. Tolaney1 ; Deborah A. Dillon3 ; Wei Li4 ; 5 ; Susanne Ramm6 ; 7 ; Adam C. Palmer6 ; 8 ; 9 ; Haluk Yuzugullu2 ; Vinay Varadan10 ; David Tuck11 ; 17 ; Lyndsay N. Harris12 ; Kwok-Kin Wong1 ; X. Shirley Liu4 ; 5 ; Piotr Sicinski2 ; 13 ; Eric P. Winer1 ; Ian E. Krop1 ; 18 ; Jean J. Zhao2 ; 14 ; 15 ; 18 ; jean_zhao@dfci.harvard.edu" class="auth_mail" title="E-mail the corresponding author
- 刊名：Cancer Cell
- 出版年：2016
- 出版时间：14 March 2016
- 年：2016
- 卷：29
- 期：3
- 页码：255-269
- 全文大小：6434 K
文摘
- •
Cyclin D1/CDK4 mediate resistance to HER2 blockade in HER2+ breast cancer
- •
CDK4/6 inhibition suppresses mTORC1, relieving inhibition of EGFR family kinases
- •
Combined CDK4/6 and HER2 inhibition is effective in transgenic and PDX mouse models
- •
CDK4/6 inhibitors delay tumor recurrence in a transgenic HER2+ breast cancer model